Accountability for Cancer Care Through Undoing Racism and Equity (ACCURE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01954641|
Recruitment Status : Completed
First Posted : October 7, 2013
Last Update Posted : August 1, 2018
Purpose: African American cancer patients, as compared to their White counterparts, continue to initiate treatment later and remain less apt to undergo complete treatment; fueling worse treatment outcomes including shorter survival. The concepts of "transparency" and "accountability," as mechanisms of systems change have been applied for decades by anti-racism organizations to civil rights and social change. Yet, the application of these concepts to health systems' change and unequal treatment has rarely been done. The Greensboro Health Disparities Collaborative and two Cancer Centers have joined together to specify structures built into cancer care systems that make cancer care vulnerable to institutional racism and investigate how they can be changed to reduce racial inequity in quality and completion of treatment for Stage 1-2 breast and lung cancer patients.
Participants: White and African American patients with first diagnosis of Stage 1-2 breast and lung cancer, with intention to treat, and their cancer care staff at 2 cancer centers. The 2 cancer centers are Cone Health Cancer Center (CHCC) in Greensboro, North Carolina and the University of Pittsburgh Medical Center (UPMC) Hillman Comprehensive Cancer Center in Pittsburgh, Pennsylvania.
Procedures (methods): Using a 5-year interrupted time-series, with an embedded randomized control trial (RCT) study design, we will test the effectiveness of the ACCURE intervention components. Having received Institutional Review Board approval for Phase 1, we completed a 5-year, retrospective review of de-identified Electronic Medical Record data to establish a baseline of repeated outcome measures, convening of an expert committee to design the intervention, and design of the real-time, electronic breast and lung cancer registry coupled with dummy testing of the registry system.
The randomized trial will compare patients who receive usual care to those who receive visits and calls from a trained ACCURE Navigator, who is well versed in issues specific to breast and lung cancer and trained to serve as a two-way communication bridge to optimize the cancer care system's accountability and transparency for equity in quality of care. Given unintended, but likely variation in implementation of the ACCURE intervention by the two Cancer Centers (at our two research sites), 6 elements of implementation and their potential effect on outcomes will be documented through a process evaluation.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Lung Cancer||Other: ACCURE Navigator Other: Usual Care by Cancer Center Care Team||Not Applicable|
The ACCURE Interventions include:
- Quality Improvement / Race specific feedback for providers regarding breast and lung surgery and adjuvant treatments.
- A real time registry with automated electronic health record feeds that provides warning signs if milestones in cancer care have not been met or if patients miss scheduled appointments
- Health Equity Training for cancer center staff at quarterly intervals
- Accure Navigation (based on special training regarding trust, culturally appropriate communication, and Kleinman's Patient Model of Illness)
- Additional efforts will be made to collect information on symptoms and side effect management from patients and medical charts.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Primary Purpose:||Health Services Research|
|Official Title:||Accountability for Cancer Care Through Undoing Racism and Equity|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||February 2018|
|Actual Study Completion Date :||March 2018|
Experimental: ACCURE Navigator
For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
Other: ACCURE Navigator
The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the "teachback" method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions.
Active Comparator: Usual Care by Cancer Center Care Team
A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
Other: Usual Care by Cancer Center Care Team
The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
- Lung Cancer - Lung Resection Surgery within 4 months of diagnosis or stereotactic radiation Breast Cancer - Completion of surgery, radiation if surgery is breast conserving, and adjuvant chemotherapy (when indicated) within 6 months of diagnosis [ Time Frame: Chart review 6 to 8 months after patient enrollment and continuous Electronic Health Record (EHR) downloads into the real time registry for the 3 years of follow up. ]Changes in race-specific proportions of quality and completion of breast and lung cancer treatment. Will examine the influence of Quality Improvement/race-specific feedback and the real time registry compared to historical controls using an interrupted time series analysis and will compare the ACCURE Navigator component to Usual Care control groups (the randomized portion of the study).
- Adherence to scheduled appointments [ Time Frame: Continuous downloads of Electronic Health Record (EHR) data into the real time registry for the 3 years of follow up or death or study withdrawal - whichever comes first. ]Will count completed appointments over scheduled appointments and look at the influence that the ACCURE Navigator has on adherence throughout the study period
- Patient satisfaction with communication [ Time Frame: Will be assessed by survey every 6 months for 3 years post enrollment or until death or study withdrawal, whichever comes first. ]Will examine the influence of the navigator on patient perceptions of communication
- Trust [ Time Frame: Will be assessed by survey every 6 months for 3 years post enrollment or until death or study withdrawal, whichever comes first. ]Will examine the influence of the ACCURE navigator on measures of Trust of the provider and health care system
- Functional Status [ Time Frame: Will be assessed by survey every 3 months in year one then every 6 months in years 2 and 3 or until death or study withdrawal, whichever comes first. ]Will assess functional status via survey and compare the various treatment modalities over time (as well as incomplete treatment).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01954641
|United States, North Carolina|
|Cone Health, Regional Cancer Center|
|Greensboro, North Carolina, United States, 27401|
|United States, Pennsylvania|
|University of Pittsburgh Medical Center, Hillman Comprehensive Cancer Center|
|Pittsburgh, Pennsylvania, United States, 15232|
|Principal Investigator:||Eugenia Eng, MPH, DrPH||University of North Carolina, Chapel Hill|
|Principal Investigator:||Samuel Cykert, MD||University of North Carolina, Chapel Hill|